Atul Pande, M.D
Atul Pande has a broad experience in strategic enterprise leadership of R&D with proven results as demonstrated by successful regulatory filings and approvals of new drugs.
Dr. Pande has experience in Neurosciences, Respiratory, HIV, Oncology and Cardiovascular therapy areas.
Suggested For You
perspectives
June 10th, 2025
Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives
perspectives
June 3rd, 2025
Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions
news
May 28th, 2025
MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award
perspectives
May 28th, 2025
A Season of Change: Why the REMS Industry Consortium Matters More Than Ever
perspectives
May 20th, 2025
Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors
perspectives
May 6th, 2025
Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn
perspectives
April 24th, 2025
How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy
perspectives
April 8th, 2025
Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements
news
April 3rd, 2025
Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution
perspectives
March 27th, 2025
Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs
news
March 19th, 2025
MMS REMS-focused Technology bolsters Full-Service REMS Solutions
webinar
April 30th, 2025
Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies